Panitumumab in Children With Solid Tumors

Amgen

Status and phase: Completed; Phase 1

Conditions: Solid Tumors

Treatments: Biological: Panitumumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT00658658

2014-005190-36 (EudraCT Number)

20050252

Details and patient eligibility

About

The primary objective of this study was to evaluate the safety and pharmacokinetics of up to 3 different dose schedules of panitumumab in pediatric patients with solid tumors.

Full description

This is an open-label, multi-center, single arm, dose-ranging, clinical study. Panitumumab will be administered by intravenous infusion to 4-6 patients per cohort. Three planned cohorts, stratified by age, will be studied at 100% of the recommended panitumumab dose for each treatment schedule as defined in adults. Enrollment will start with a 2.5 mg/kg once weekly administration to the 12 to < 18 year old patients. Upon demonstration of sufficient safety additional cohorts will open; a 2.5 mg/kg once weekly administration to the 1 to < 12 year old patients and a 6.0 mg/kg once every two weeks to the 12 to < 18 year old patients. The decision to advance to the next cohort will be based on observance of ≤ 33% incidence of a dose limiting toxicity during the evaluation period. Subsequent cohorts of 6.0 mg/kg once every two weeks to the 1 to < 12 year old patients and 9.0 mg/kg once every three weeks to both age groups will open once sufficient safety in each cohort is determined. Participants may stay on study treatment until disease progression.

Enrollment: 31 patients

Sex: All

Ages: 1 to 17 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Parents or legal guardian signed-written informed consent
• 1 to < 18 years of age
• Histologically or cytologically confirmed solid tumor that has recurred after standard therapy, or for which there is no standard therapy. Subjects with brainstem glioma DO NOT need histologic proof of the diagnosis.
• Paraffin-embedded tumor tissue from primary tumor or metastasis for determination of epidermal growth factor receptor expression and biomarker testing
• Central nervous system tumors are allowed
• Presence of measurable or non-measurable disease.
• Life expectancy of ≥ 12 weeks.
• Performance status: Karnofsky ≥ 60% for 12 to <18 years of age; Lansky play scale ≥ 60% for 1 to < 12 years of age.
• Adequate hematologic function.
• Adequate renal function.
• Adequate hepatic function.
• Magnesium ≥ lower limit of normal (LLN)
• Adequate pulmonary function
• All previous therapy-related toxicities must have resolved or return to baseline.

Exclusion criteria

• Diagnosis of leukemia, non-Hodgkin's lymphoma, Hodgkin's disease or other hematologic malignancy.
• Any prior allogeneic transplant.
• Prior autologous bone marrow or peripheral stem cell transplant less than 3 months prior to enrollment.
• Substantial radiotherapy to the bone marrow within 6 weeks prior to enrollment.
• Prior use of any monoclonal antibodies directly targeting the epidermal growth factor receptor (EGFr). Subjects who have received prior tyrosine kinase inhibitors such as gefitinib or erlotinib are eligible.
• Immunotherapy, radiotherapy, or chemotherapy ≤ 2 weeks prior to enrollment. (≤ 6 weeks for nitrosoureas, mitomycin-C, and liposomal doxorubicin, and ≤ 6 weeks from prior antibody therapy).
• Requirement to receive concurrent chemotherapy, immunotherapy, radiotherapy (except for pain control) or any other investigational drug while on this study.
• Prior seizures < 3 months prior to enrollment. Subjects with a history of seizure disorders ≥ 3 months prior to enrollment must be seizure free and on stable anticonvulsant medication(s) for ≥ 3 months prior to enrollment).
• Presence of a serious uncontrolled medical disorder.
• Dementia, altered mental status, or any other medical condition or disorder that would prohibit the understanding or rendering of assent (if applicable), or ability to comply with study procedures.
• Major surgery ≤ 28 days prior to enrollment.
• Known or suspected history of interstitial lung disease.
• Active inflammatory bowel disease or other bowel disease causing chronic diarrhea.
• Known positive test for human immunodeficiency virus infection, hepatitis C virus, acute or chronic hepatitis B infection, or any co-morbid disease that would increase risk of toxicity.
• Females of childbearing potential not using adequate contraception precautions for the duration of the study treatment and for 2 months after the last administration of investigational product.
• Pregnant or breast-feeding, or planning to become pregnant during study treatment and within 2 months after the last administration of investigational product.
• Received investigational therapy or procedure ≤ 30 days prior to enrollment.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

31 participants in 1 patient group

Panitumumab

Experimental group

Description:

Participants received panitumumab at planned doses ranging from 2.5 mg/kg weekly (QW) to 9.0 mg/kg every 3 weeks (Q3W) until the patient experienced disease progression, was unable to tolerate study drug, withdrew consent, or other reasons that warranted removal from the study.

Treatment:

Biological: Panitumumab